Therefore, therapeutics strategies based on S1P pathway have been adopted to limit the effects of S1P signaling in cancer, including the reduction of the released S1P (36), inhibition of SK1 and/or SK2 (37) and targeting of specific S1P receptors (38). This evidence concerns the gene MBTPS1 and cancer.